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*e measurement of body composition (BC) represents a valuable tool to assess nutritional status in health and disease. *e most
used methods to evaluate BC in the clinical practice are based on bicompartment models and measure, directly or indirectly, fat
mass (FM) and fat-free mass (FFM). Bioelectrical impedance analysis (BIA) and dual energy X-ray absorptiometry (DXA)
(nowadays considered as the reference technique in clinical practice) are extensively used in epidemiological (mainly BIA) and
clinical (mainly DXA) settings to evaluate BC. DXA is primarily used for the measurements of bone mineral content (BMC) and
density to assess bone health and diagnose osteoporosis in deﬁned anatomical regions (femur and spine). However, total body
DXA scans are used to derive a three-compartment BC model, including BMC, FM, and FFM. Both these methods feature some
limitations: the accuracy of BIA measurements is reduced when speciﬁc predictive equations and standardized measurement
protocols are not utilized whereas the limitations of DXA are the safety of repeated measurements (no more than two body scans
per year are currently advised), cost, and technical expertise. *is review aims to provide useful insights mostly into the use of BC
methods in prevention and clinical practice (ambulatory or bedridden patients). We believe that it will stimulate a discussion on
the topic and reinvigorate the crucial role of BC evaluation in diagnostic and clinical investigation protocols.
1. Introduction
*e human body comprises more than thirty measurable
components [1]. A direct in vivo measurement of body
components is currently not possible; consequently, indirect
methods andmodels have been developed to do that. Within
this framework, the World Health Organization (WHO)
deﬁnes “nutritional status” as the condition of the body,
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resulting from the balance of intake, absorption, and utili-
zation of nutrients interacting with individual physiological
and pathological status.
*e most frequently applied model to evaluate body
composition (BC) in clinical practice and epidemiology
splits the body into fat mass (FM) and fat-free mass (FFM),
i.e., the bicompartmental model. FM indicates the water-free
body component; the remaining body components (skeletal
muscle, internal organs, and interstitial fat tissue) are in-
cluded in the FFM. *e most accurate methods to measure
FM and FFM according to the bicompartment model are
densitometry (underwater weighing), hydrometry (deute-
rium dilution), Echo-MRI, and total body potassium (TBK)
counting. However, these methods are characterized by
complex measurement protocols and require specialized
expertise and costly equipment, making their application in
clinical settings limited.
Bioimpedance analysis (BIA) is a widely used method to
evaluate BC for both epidemiological and clinical purposes;
it measures the electrical properties of body tissue and es-
timates BC parameters as total body water (TBW) and FFM
BC parameters (see methods).
BIA is a noninvasive, low cost, and reliable method for
BC assessment in clinical and nonclinical settings. *e basic
principle of the BIA technique is that the transit time of a
low-voltage electric current through the body depends on
BC characteristics [2]. However, this methodology has
limitations due to the chemical composition of FFM
(i.e., water, proteins, glycogen, and minerals) because of
considerable inter- and intraindividual variability as a
consequence of changes in FFM occurring with growth,
maturation, ageing, and disease states [3].
Dual energy X-ray absorptiometry (DXA) is the current
reference method for the assessment of BC, mainly because
it provides accurate estimates of bone mineral, fat, and lean
soft tissue (the so called three-compartment model) [4].
DXA utilizes low-emission X-rays to measure the attenua-
tion of incident X-ray beams when they pass through body
tissues (high attenuation for bone and low attenuation for
fat).
*e assessment of bone health to establish diagnosis of
osteoporosis and fracture risk requires DXA for evaluating
bone mineral density (BMD) in selected anatomical regions
of interest (e.g., spine and femur). In addition, DXA is
capable of providing estimates of visceral fat using validated
predictive algorithms [5] and furnishes a measure of truncal
fat mass, which has been found to be predictive of disease
risk [6].
*is review aims to summarize the scientiﬁc background
of BIA andDXA and to furnish a comprehensive overview of
their theoretical/technical concepts and application in
bedridden and ambulatory patients and the information
they can provide on drug pharmacokinetics.
2. Assessment of BC by BIA
BIA measures the electrical properties of body tissues and
represents a useful approach for estimating body composition
parameters such as TBW and FFM. In the bicompartment
model, the human body is composed of FFM, which includes,
under physiological conditions, the following components:
bone mineral content (≈7%), extracellular water (≈29%),
intracellular water (≈44%), and visceral protein (�20%). BIA
estimation of body composition is based on body ﬂuid vol-
ume measurement using BIA resistance value [2, 7, 8].
Bioelectrical impedance, or bioimpedance (Z, Ω), is
deﬁned as the opposition of a conductor to the ﬂow of an
alternating electrical current applied to it. Bioimpedance
varies with tissue composition as well as with the frequency
of the applied current. Bioimpedance is a complex parameter
derived from the vector relationship between resistance (R,Ω), which arises from intracellular and extracellular ﬂuids,
and reactance (Xc, Ω), which is related to the capacitance of
the cell membrane [7]. Although the human body is not a
uniform cylinder, an empirical relationship can be estab-
lished between the ratio height2/R (cm2/Ω 50 kHz), deﬁned
as bioimpedance index (BI) measured at 50 kHz, and the
volume of TBW, approximately 73% of FFM in healthy
individuals.
Single-Frequency-BIA (SF-BIA), generally at 50 kHz, is
passed between surface electrodes placed on hand and foot.
Some BIA devices use other electrode placements, such as
foot-to-foot or hand-to-hand electrode (Bipedal BIA). Many
studies have compared multifrequency hand-to-foot (HF-
BIA) and foot-to-foot (FF-BIA) bioimpedance analysis in
order to assess diﬀerences in FFM values in populations with
a wide range of body mass index (BMI) [9, 10] and they
found that FF-BIA gives lowest values of FFM in overweight
and obese subjects, also if compared with the results of the
DXA [11]. In clinical practice, BIA allows monitoring of
body ﬂuids (extracellular/intracellular ratio) and therefore
patients’ nutritional status, in the short time and long time
[12, 13].
2.1. Phase Angle. *e phase angle, or PA ((R/Xc)× (180/π)),
expressed in degrees) reﬂects the ratio between intra- and
extracellular water. It may be aﬀected by nutritional and
hydration status [2] (Figure 1). In healthy subjects, PA
ranges between 6° and 7° [14], and in athletes it may reach
8.5° [15]. Low PA (<5°) indicates the loss of cellular integrity
[16–18]. *e PA appears to be a more sensitive indicator of
nutritional status compared to impedance since it is closely
associated with cellular integrity [19–22].
2.2. Multifreqency BIA and BIA Spectroscopy. BIA can be
performed using simultaneously electrical current with
diﬀerent frequencies. *e application of more than two
frequencies, ranging from low (1 kHz) to high (500 kHz)
frequencies, allows themeasurement of TBW, FFM, FM, and
ICW and ECW compartments. At low frequencies (1–
5 kHz), the electric current does not penetrate the cell
membrane, and therefore it is assumed that the current
passes through the extracellular ﬂuid. Conversely, at higher
frequencies (>50 kHz), the current passes through the cell
membranes and it is associated with both intracellular and
extracellular ﬂuid compartments [23–25]. Frequencies
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higher than 100 kHz do not improve the accuracy of body
composition estimation (Figure 2).
Bioimpedance spectroscopy (BIS) diﬀers in the un-
derlying, theoretical basis from the more commonly applied
single-frequency BIA, because it does not require the use of
statistically derived, population-speciﬁc prediction equa-
tions. One of the main advantages of the BIS is its ability to
diﬀerentiate between ECW and ICW. BIS has been found to
be accurate for measuring changes in ﬂuid volumes [26].
2.3. Bioelectrical Impedance Vector Analysis (BIVA). In the
BIVA approach, introduced by Piccoli et al., [27] R and Xc
(R-Xc graph), obtained at 50 kHz, are normalized to height
(R/ht and Xc/ht, respectively), and plotted as bivariate
vectors (Figure 3). BIVA allows a direct assessment of body
ﬂuid volume through patterns of vector distribution on the
R-Xc plane without the knowledge of the body weight.
Reference tolerance ellipses (50, 75, and 95%) for the in-
dividual vector were previously calculated in the healthy
population and speciﬁc patient populations. Bioelectrical
vectors are analyzed by evaluating their position with respect
to reference values (tolerance ellipses): a signiﬁcant decrease
in body hydration shifts the vector towards the upper pole of
the ellipse major axis, whereas ﬂuid retention moves it in the
opposite direction. *e vector shifts along the minor axis of
the ellipse according to individual soft tissue body cell mass,
shifting on the left side with more cell mass.
2.4. Assessment of Body Composition by Dual Energy X-Ray
Absorptiometry (DXA). Among diﬀerent methods of body
composition measurements, DXA provides whole body and
regional estimates of three main components: FM, lean body
mass (LBM), and bone mineral content (BMC). Several
options are available as the ﬁrst choice to investigate visceral
fat, such as magnetic resonance imaging (MRI) or computer
tomography (CT) scanning, because they provide a quan-
titative and qualitative assessment of visceral (pre- and
postperitoneal) and subcutaneous (superﬁcial and deep)
adipose tissue [28,29]. However, costs, technical staﬀ and
expertise, contraindications, and accessibility to these
methods are important limitations. *erefore, DXA is also
used to investigate visceral fat.
DXA uses a source that generates X-rays, a detector, and
an interface with a computer system for imaging the scanned
areas of interest. *e eﬀective radiation doses involved are
small (1–7 μSv), making the technique widely applicable. Due
to DXA’s advantages in terms of accuracy, simplicity, avail-
ability, and relatively low expense as compared to procedures
like TBK,MRI or CT IMAGING, and low radiation exposure,
DXA measurement is becoming increasingly important,
emerging as reference assessment technique also in muscle
mass evaluation [30]. DXA systems are practical, require no
active subject involvement, and impose minimal risk
[20, 31, 32]. Radiation exposure from a whole body DXA scan
is equivalent to between 1 and 10% of a chest X-ray [20].
Moreover, unlike most other body composition methods that
are designed to quantitate a single whole body component,
DXA allows quantiﬁcation of multiple whole body and re-
gional components. As a result, DXA is gaining international
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acceptance as a body composition reference method [33],
particularly in severe malnutrition and overweight/obesity.
2.5. Clinical Indications to BIA Utilization. Being a non-
invasive method, BIA allows to follow body composition
modiﬁcations in time, for example, in case of weight loss
during acute or chronic diseases or, on the contrary, during
weight gain, oﬀering the possibility to have a prognostic
forecast [34].
Anyway, there are several factors that can aﬀect the BIA
results, such as nonstandardization of body position, pre-
vious physical exercise, and food or ﬂuid intake [35]. Also,
diﬀerent predictive equations have been developed to esti-
mate TBW and FFM which include several parameters such
as sex, age, and body weight. *ese predictive equations are
generally population-speciﬁc and device-speciﬁc and can be
useful only in individuals with the same characteristics of the
reference population and with a physiological hydration
status [2].
In addition, pathological conditions could modify the
individual’s hydration level (dehydration/edema). Hence,
existing equations for FFM could not be used, in as much as
they do not make a distinction between the amount of
intracellular and extracellular water. *e development and
validation of speciﬁc equations is mandatory and should be
the focus of future studies.
Regarding PA, it is a useful parameter in clinical practice
as it allows identiﬁcation and monitoring of patients at risk
of impaired nutritional status and decreased survival, such as
HIV/AIDS, cancer, anorexia, liver cirrhosis, hemodialysis,
and pulmonary disease geriatric and surgical patients
[21, 36–40].
Few studies have also addressed the possibility to apply
PA in Sport Medicine to evaluate physical performance
[41–43]. Silva et al. [32] described a positive correlation
between handgrip strength and PA in elite judo athletes
during a competition. Recently, Marra et al. [33] showed in a
team of elite endurance cyclists, evaluated during their
participation to a tournament-cycling race (Giro d’Italia), a
signiﬁcant and progressive reduction of PA. *e reduction
of the PA suggests a loss of intracellular water (ICW), which
could be explained by the long-term competition and
continuous vigorous exercise [44]. *at study [44] showed
that PA is a useful method for monitoring body composition
and for obtaining information on the cell integrity, even if its
relationship with sports performance is not readily evident.
For this reason, in the future, it is advisable to conduct
studies in elite athletes to verify the link between the PA and
muscle strength and performance.
Despite the close correlation between nutritional status
and phase angle, however, not all studies found the phase
angle a reliable indicator of disease-related malnutrition.
*is led to the use of BIVA approach as an alternative tool to
assess and monitor patients’ hydration and nutrition status
in several pathologic conditions, such as hemodialysis [45]
or ambulatory peritoneal dialysis [46], liver cirrhosis [47],
critically ill [48], and obese patients with stable and changing
weight [49], because of its independence from regression
equations in the calculation of lean body mass and fat mass
and body weight.
In such a way, BIVA enables a more detailed un-
derstanding of hydration status and cell mass compared to
phase angle alone. Since phase angle is calculated from
reactance and resistance, diﬀerent positions of the vector in
the R-Xc graph can theoretically produce identical phase
angles (Figure 3). Diﬀerentiation between obese (high phase
angle, short vector) and athletic subjects (high phase angle
and long vector) is consequently possible by BIVA just as
discrimination between cachectic (low phase angle and long
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vector) and lean subjects (normal phase angle and long
vector).
In conclusion, bioelectrical phase angle and BIVA
represent a clinical approach to body composition, free from
prediction equations-inherent errors and assumptions, al-
though quantities of body compartments are not measured.
3. Clinical Indications to Use DXA
DXA is routinely used in clinical practice for the mea-
surement of bone mineral tissue, allowing the diagnosis and
the follow-up of osteoporosis, a potentially high-risk con-
dition characterized by malabsorption, malnutrition, and
long-term corticosteroid therapies, frequently observed in
post menopause and in several chronic diseases.
*e use of DXA for the assessment of body composition
in daily clinical practice should be extended to overweight/
obese patients in order to better evaluate their long-term
cardiovascular and oncologic risk related to excessive
adiposity.
BMI changes determined at individual level do not dis-
tinguish between increased body weight due to fat or nonfat
mass. Indeed, WHO has deﬁned BMI a good measure of
adiposity at the population level, but a “surrogate” measure of
adiposity at the individual level [50]. DXA measures excess
adiposity with more accuracy than BMI, but, although
promising, it is premature to recommend its routine use for
the diagnosis of obesity because there have been few clear
statements regarding its clinical indication for body compo-
sition assessment in patients outside the research setting [51].
However, DXA could be used to monitor changes in lean and
fat tissues in obese subjects undergoing major weight losses,
such as after bariatric surgery [52, 53]. In this condition, body
weight might not change, but body composition might change
during weight loss interventions. DXA allows to quantify total
fat and lean soft tissue and also truncal and visceral fat [52],
which are useful in the evaluation of cardiometabolic risk
[54, 55]. *erefore, DXA may represent a method for clinical
assessment of weight changes and/or training programs on fat
and FFM compartments [51]. DXA analysis can also be used in
patients with sarcopenia [30, 51]. *is condition involves a
decreased skeletal muscle mass and strength, and it is usually
described in the elderly. Similarly to obesity, it is considered a
risk factor for metabolic disease [56]. When sarcopenia and
obesity occur concomitantly in an individual, the condition is
referred to as sarcopenic obesity (SO) [57].
Using DXA, we could also acquire information on the
three compartments (lean, fat, and bone) of the body, and
four regions (i.e., head, trunk, arms, and legs) so as to obtain
information on the eﬃcacy of treatment in osteoporosis and
other clinical conditions related to bone turnover.
Other examples of clinical indications to DXA are the
following:
3.1. Pediatric Age. Body composition analysis in children
provides a window into the complex changes that occur
throughout childhood and gives the opportunity for un-
derstanding metabolic and physiological correlations
[50, 51, 58]. DXA has the ability to evaluate nutritional status
and growth disorders by analyzing the individual com-
partments of the body, thus oﬀering the opportunity for
studying skeletal maturation and mineral homeostasis in
relation to environmental and/or pathological factors in-
volved in the development [59–62].
3.2. Patients with HIV. DXA total body composition with
regional analysis can be used in HIV patients to assess fat
distribution in those using antiretroviral agents who are at
risk of lipoatrophy [51]. DXA allows to detect the individual
and independent eﬀects of antiretroviral agents on pe-
ripheral (arm and leg) and central (trunk) fat. DXA has been
demonstrated to be a highly sensitive and consistently re-
liable technique for detecting changes in fat distribution over
a relatively short period (e.g., months) before clinically
apparent lipodystrophy develops [51, 58].
3.3. Patients Candidate or Treated with Bariatric Surgery.
DXA can be used in obese subjects undergoing bariatric
surgery in order to monitor lean and fat mass changes.
Repeat scans could be done at 3months after bariatric
surgery. Early detection of lean soft tissue decline during
weight loss may prompt clinical recommendations for in-
creasing physical exercise and more appropriate dietary
advice [51, 63, 64], even though practical considerations
limit the use of DXA in severely obese subjects.
3.4. Safety ofDXA. *ere are no contraindications to the use
of DXA in the clinical practice with the exception of
pregnancy [65]. However, being a radiological procedure,
DXA should be performed no more than twice per year,
which is comparable to the exposure to an intercontinental
ﬂight, thus not requiring strict monitoring, at least in some
patients [51].
4. Body Composition and Pharmacokinetics:
A Window of Opportunities for
Research and Therapeutics
*ere is still scant awareness on the issue that responses to
drugs can be aﬀected by changes in body composition. Even
though obesity and cachexia, at the extremes, may interfere
with drug pharmacokinetics and pharmacodynamics at
multiple levels, the most relevant eﬀects are on drug dis-
tribution, i.e., on the diﬀusion of drugs from the blood to the
tissues [66–68]. Given that the total amount of a drug that
moves from the blood into its distribution compartment
(mainly fat mass for lipophilic drugs and fat-free mass for
hydrophilic drugs) depends on the size of the compartment,
drug distribution will be aﬀected by body composition
status. When a drug is administered to a patient with its
relative distribution compartment(s) larger than that of
normal, its peak concentration in plasma will be lower and
the time for its disappearance from blood longer than
normal, leading to smaller but longer pharmacological ef-
fects [67, 68].
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Conversely, higher peak concentrations and shorter
persistence in plasma are expected when its distribution
compartment is smaller than normal, suggesting that, in
these conditions, toxicity could be higher even in the setting
of a lower clinical eﬃcacy. *e pharmacokinetic conse-
quences of the expansion of drug distribution compartments
have been studied in more details in general anesthesia in
obese patients [68, 69]. Moreover, it has been repeatedly
suggested that underdosing drug could be a very common
problem in obese patients [70–72] and strategies for dose
corrections in morbid obesity have been established
[68, 73, 74]. However, the information for several classes of
drugs in obesity is still very limited, and strong eﬀorts are
needed to address this issue.
In addition, until recently, little attention has been paid
to the eﬀects of the decrease in fat and/or fat-free mass on the
pharmacokinetics of drugs in sarcopenic conditions, with
the exception of few studies performed in selected patho-
logic conditions such as AIDS [75]. *e interest on this issue
boosted in the recent years after the publication of a series of
inﬂuential papers showing that the dose-dependent toxicity
of hydrophilic antineoplastic drugs such as 5-FU or cape-
citabine is higher in sarcopenic patients and inversely related
with psoas muscle surface area measured by CT scan at the
level of L3 [76]. *is observation ﬁts well with the evidence
that FFM and, especially skeletal muscle mass, represents the
main distribution compartment for these drugs [68]. *e
issue of drug distribution in muscles and its consequences in
neoplastic patients with sarcopenia is further complicated by
the evidence that some transduction therapy agents, such as
sorafenib, may reduce muscle mass by a direct action [77].
*is suggests potential, new, and unexpected interactions
between diﬀerent combination chemotherapy protocols
with drugs that directly aﬀect the size of the distribution
compartments. Researches speciﬁcally focused on dose
adjustments of drugs, according to body composition
characteristics, are warranted for a precision, personalized
therapy.
5. Future Directions
*is review highlighted the relevance of body composition
assessment and monitoring by BIA and DXA in the eval-
uation of nutritional status in several pathological condi-
tions. However, for a wider clinical application, some issues
related to these techniques should be addressed.
Future investigations on BIA could include the
following:
(i) Improving validation of BIA equations according to
age, sex, and ethnicity
(ii) Developing speciﬁc equations for under or over-
hydrated patients
(iii) Developing PA prognostic/survival predictive
values in pathological conditions
(iv) Accurate validation of MF-BIA, segmental BIA, and
BIS in conditions of body ﬂuid abnormalities (heart,
liver, kidney diseases, etc.)
For DXA, future developments could be the following:
(i) Individuating factors that aﬀect the accuracy of the
methods, such as subject’s body shape and size,
calibration procedures, software version, and in-
strumental models
(ii) Advanced analysis techniques that signiﬁcantly
reduce the impact of motion artifacts on infant DXA
scans
(iii) Highly standardized and reproducible patient po-
sitioning and image analysis procedures to accu-
rately measure axial, appendicular, and segmental
regions of interest
(iv) Assessing how changes in fat distribution aﬀect the
accuracy of estimates/measurements, in as much as
an estimated body composition by DXA changes
with age, exercise, and diet
Finally, future studies appear mandatory to better un-
derstand the relationship between pharmacokinetics and
pharmacodynamics of diﬀerent drugs and BC in diﬀerent
nutritional states.
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